ArticleFrontiers in cell and developmental biology2026
MAML-residual transformer for few-shot prediction of targeted therapy response in NSCLC.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-small cell lung cancer (NSCLC) exhibits high heterogeneity, and the scarcity of annotated imaging data limits the robustness and generalization capability of conventional deep learning approaches, particularly in few-shot scenarios. Therefore, developing accurate and generalizable prediction models under limited sample conditions remains a critical challenge for precision oncology. Methods: In this study, we proposed a Model-Agnostic Meta-Learning_RT (MAML_RT) framework for predicting targeted therapy response in NSCLC. The framework integrates model-agnostic meta-learning with residual transformers. Multi-task meta-training was employed to learn highly generalizable parameter initializations, enabling rapid adaptation to new cohorts with limited labeled samples. Meanwhile, the multi-head self-attention mechanism of the residual transformer was utilized to model global correlations among radiomics features and capture long-range dependencies between diverse tumor phenotypic characteristics. Results: In a cohort of 300 patients, MAML_RT achieved an accuracy of 0.91 and an area under the receiver operating characteristic curve (AUC) of 0.93 for predicting targeted therapy efficacy. Under an extremely small-sample scenario (n = 50), the model maintained an AUC of 0.76, significantly outperforming the comparison models. Furthermore, on an independent external validation cohort, MAML_RT achieved an AUC of 0.85 and an accuracy of 0.88, demonstrating its cross-center generalization capability. Discussion: The proposed MAML_RT framework provides an effective solution for targeted therapy response prediction in NSCLC under limited labeled data conditions. By integrating meta-learning with residual transformer-based feature modeling, this approach improves model adaptability and generalization, offering potential support for clinical decision-making and individualized treatment stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.